Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
BRANFORD, Conn., Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioXcel Corporation, a global leader in developing cloud-based big data platforms and transformative patient treatments, today announced a strategic big data collaboration with Centrexion Therapeutics to develop a portfolio of clinical pain therapeutic assets.
Centrexion is focused on developing and commercializing new treatments for chronic pain with better efficacy and safety than current treatment paradigms. Through this collaboration, Centrexion will leverage BioXcel's first-in-class Big Data Innovation Lab (BDI-Lab) to generate optimal therapeutic value at the intersection of pain biology and differentiated products with a higher probability of clinical and commercial success. This complex association of drugs and disease will involve big data analytics to decipher network pharmacology combined with deep expertise to generate product development blueprints for transformational pain therapeutics.
“This partnership allows us to combine our distinctive translational medicine approach with BioXcel’s world-class big data platform and discovery engine to develop new non-opioid therapies to treat chronic pain. We are pleased to partner with BioXcel on this important initiative and to deliver new and innovative solutions to patients in need,” said Kerrie Brady Chief Business Officer, Centrexion Therapeutics.
"We are excited to partner with Centrexion to support the development of innovative treatments for chronic pain," stated Frank D.Yocca Senior Vice President, CNS Research & Development, BioXcel Corporation. “Our Big Data Innovation Lab has diverse application in CNS diseases and across multiple therapeutic areas, as evident from our partnerships with Takeda, Alexion, Pronutria and many others. We expect that the combination of our respective capabilities will drive significant improvements in the speed and efficiency of Centrexion’s drug development initiatives.”
Under the terms of the agreement, BioXcel will receive an upfront payment, as well as development and commercial milestone payments. Financial details are not disclosed.
About BioXcel
BioXcel is a global leader in providing cloud-based Pharma big data solutions for discovering novel products and performance benchmarking of pipeline innovation and marketed products in all major therapeutic areas. Our first in class Big Data Innovation Lab is focused on the development of transformative patient treatments for strategic portfolio growth and leverages; PharmGPS® - a live analytics platform; an Integrated Center of Xcellence housing multidisciplinary scientific, commercial and medical teams; and a drug development team that offers deep domain expertise. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
Contact: BioXcel Corporation Anita Ganjoo Corporate Communications Email: [email protected] Tel: 203 957 2487
